Home » Topics » Conferences

Conferences
RSS

Spotlight on 5-HT1B/1D agonists for migraine

July 1, 1998

Different schedules, doses of DX-8951f assessed in phase I

July 1, 1998

TZT-1027: mechanism of action and phase I results

July 1, 1998

Phase I trial results for AG-2034 presented at NCI-EORTC symposium

July 1, 1998

Agouron in-licenses S-1153; phase I results presented at AIDS conference

June 30, 1998

DPPE proves highly effective and well tolerated in metastatic breast cancer patients

June 30, 1998

No dose-limiting toxicity found yet for AN-9 in phase I

June 30, 1998

Hydroxyurea in combination regimens enhances anti-HIV activity

June 30, 1998

Early studies with JE-2147 yield promising results

June 30, 1998

Parke-Davis discusses development of potent, irreversible EGF receptor TK inhibitors

June 30, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...